Psoralen plus ultraviolet-A-bath photochemotherapy as an adjunct treatment modality in cutaneous chronic graft versus host disease

Photodermatology Photoimmunology and Photomedicine

Volumn 18, Issue 4, 2002, Pages 183-190

  Leiter, Ulrike ^a,b   Kaskel, Peter ^a   Krähn, Gertraud ^a   Gottlöber, Petra ^a   Bunjes, Donald ^a   Peter, Ralf Uwe ^a   Kerscher, Martina ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

20 MHz ultrasound; Cutaneous chronic GVHD; PUVA bath therapy

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHOXSALEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PSORALEN; STEROID;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CATARACT; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ERYTHRODERMA; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; LICHENOID ERUPTION; MALE; MULTIPLE MYELOMA; NAUSEA; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; PUVA; RELAPSE; REMISSION; SCLERODERMA; SKIN MANIFESTATION; SKINFOLD THICKNESS; SUNBURN; ULTRASOUND; ULTRAVIOLET A RADIATION; VOMITING;

ADULT; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; COMBINED MODALITY THERAPY; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PHOTOTHERAPY; PREDNISONE; PUVA THERAPY; SKIN; SKIN DISEASES; STEM CELL TRANSPLANTATION;

EID: 0036693676     PISSN: 09054383     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0781.2002.00719.x     Document Type: Article

References (29)

1. Treatment of chronic graft versus host disease with ultraviolet irradiation and psoralen (PUVA)
2. Improving the outcome of bone marrow transplantation by using CD 52 monoclonal antibodies to prevent graft versus host disease and graft rejection
3. Ex vivo T-cell depletion with the monoclonal antibody CAMPATH-1 plus human complement effectively prevents acute GVHD in allogenic bone marrow transplantation
4. For CAMPATH users: Control of graft versus host disease and graft rejection by T-cell depletion of donor and recipient with CAMPATH antibodies. Results of matched sibling transplants for malignant diseases
5. Successful use of extracorporal photochemotherapy in the treatment of severe acute and chronic graft versus host disease
6. 8-methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft versus host disease
7. Photochemotherapie (PUVA) der akuten GraftVersus-Host-Erkrankung
8. PUVA therapy for drug resistant graft versus host disease
9. Photochemotherapy improves chronic cutaneous graft-versus-host disease
10. Phototherapy in the treatment of cutaneous graft versus host disease
11. Treatment of localized scleroderma with PUVA bath photochemotherapy
12. Puva-bath photochemotherapy resulting in rapid clearance of lymphomatoid papulosis in a child
13. PUVA therapy for psoriasis. Comparison of oral and bath-water delivery of 8-methoxypsoralen
14. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis. A possible cellular basis for remittive therapy
15. PUVA bath photochemotherapy for localized scleroderma. Evaluation of 17 consecutive patients
16. Induction of intestinal collagenase by UVA1-phototherapy in morphea fibroblasts
17. Clinical manifestations of graft versus host disease in human recipients of marrow from HLA-matched sibling donors
18. Chronic graft versus host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients
19. Soleil et peau
20. Chronic cutaneous sclerodermoid graft versus host disease: Evaluation by 20 MHzsonography
21. Methoxalen and ultraviolet-A irradiation in treatment of chronic cutaneous graft versus host reaction
22. Psoralen plus ultraviolet A (PUVA) in the treatment of chronic graft vs. host disease: Preliminary experience in standard treatment resistant patients
23. Photoinactivation of T-cell function with psoralen and UVA radiation suppresses the induction of experimental murine graft versus host disease across major histocompatibility barriers
24. Mechanism of UVB-induced impairment of the antigen presenting capacity of murine epidermal cells
25. PUVA therapy decreases HLA-DR+CD1a+ Langerhans cell in human skin, but flow cytometrically sorted residual HLA-DR+ CD1a+ Langerhans cells exhibit normal alloantigen presenting function
26. Increased serum levels of tumor necrosis factor a precede major complications of bone marrow transplantation
27. Ultraviolet A1 irradiation differentially affects cytokine production by atopen-specific human T-helper cells
28. Ultraviolet radiation effects on human keratinocyte ICAM-1 expression: UV induced inhibition of cytokine induced ICAM-1 mRNA expression is transient, differentially restored for IFN-γ versus TNFα, and followed by ICAM-1 induction via a T
29. Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy